Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights

In This Article:

Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc.

-  Initiated ARTEMIS, the first-ever registrational intravitreal gene therapy trial, in both treatment-experienced and treatment-naive patients with wet AMD

-  Presented the first human data mapping cell-level transduction and aflibercept mRNA expression 3.5 years after Ixo-vec administration, establishing the potential for life-long vision preservation

REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy to preserve sight for life in highly prevalent ocular diseases, today reported financial results for the first quarter of 2025. The company also provided pipeline highlights and anticipated milestones.

“We’ve kicked off 2025 with strong execution by initiating ARTEMIS, our first pivotal trial for Ixo-vec, and are thrilled with the enthusiasm of retina specialists and patient interest. We look forward to starting our second registrational study, AQUARIUS, later this year,” stated Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies. “The long-term data from OPTIC and LUNA, along with the anticipated two-year follow-up data from LUNA, bolster confidence in Ixo-vec's potential to provide One And Done™ life-long injection-free vision preservation for wet AMD patients. Additionally, new data presented at ARVO showcase the first human cell-level mapping of Ixo-vec transduction and aflibercept mRNA expression, supporting its differentiated clinical profile. Ixo-vec has demonstrated robust retinal transduction and sustained therapeutic levels, establishing a product profile that was overwhelmingly preferred by LUNA patients over their previous frequent anti-VEGF injections. If approved, Ixo-vec may ensure continued anti-VEGF protection for the many wet AMD patients who are lost to follow-up within just 2 to 3 years, and we expect that it will offer a compelling value proposition for retina practices."

Ixo-vec Recent Program Highlights

Initiated ARTEMIS, the first-ever registrational intravitreal gene therapy trial in patients with wet AMD

  • ARTEMIS continues to enroll both treatment-experienced and treatment-naïve patients.

  • ARTEMIS is a US-based study evaluating a single administration of Ixo-vec (6E10 vg/eye) compared to on-label aflibercept (2mg) every 8 weeks in approximately 284 patients with wet AMD.

  • ARTEMIS is the first of two planned Phase 3 registrational trials to evaluate Ixo-vec in patients with wet AMD. Details on the second study, AQUARIUS, are forthcoming.